Management of hypertension in patients with COVID-19: Implication of angiotensin-converting enzyme 2.
| Autor: | Jia GH; Department of Medicine-Endocrinology; Department of Medical Pharmacology and Physiology, University of Missouri School of Medicine, Columbia, MO 65212., Sowers JR; Department of Medicine-Endocrinology; Department of Medical Pharmacology and Physiology, University of Missouri School of Medicine; Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO 65212, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cardiology plus [Cardiol Plus] 2021 Oct 01; Vol. 6 (4), pp. 210-217. Date of Electronic Publication: 2021 Dec 30. |
| DOI: | 10.4103/2470-7511.334397 |
| Abstrakt: | The global coronavirus disease-19 (COVID-19) pandemic, caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has created an unprecedented, global public health crisis. Epidemiological studies showed that hypertension is a frequent comorbidity, as well as an independent prognostic risk factor in patients with COVID-19. Angiotensin-converting enzyme-2 (ACE-2) is a receptor for SARS-CoV-2, and thus essential for viral entry into human cells. This review summarizes the recent findings of epidemiology of hypertension in COVID-19 patients and highlights the critical role of ACE2. We also review the impact of endothelial dysfunction, inflammation, and arterial stiffness in promoting hypertension and cardiovascular disease in COVID-19 patients. This review also discusses therapeutic strategies for managing hypertension in patients with COVID-19, with particular emphasis on ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers. Competing Interests: There are no conflicts of interest. (Copyright © 2021 Cardiology Plus. Published by Wolters Kluwer - Medknow.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|